Afelimomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Afelimomab
Monoclonal antibody
Type F(ab')2 fragment
Source Mouse
Target TNFα
Clinical data
ATC code L04AB03 (WHO)
Identifiers
CAS Number 156227-98-4 N
ChemSpider none
KEGG D07436 YesY
 NYesY (what is this?)  (verify)

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]

References[edit]

  1. ^ Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624Freely accessible. PMID 16277704. 
  2. ^ Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–2182. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.